Journal article icon

Journal article

Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity

Abstract:

The introduction of biologic disease modifying anti-rheumatic drugs (bMDARDs) have revolutionised the treatment of psoriatic arthritis (PsA). This, combined with a ‘treat-to-target’ approach, means that achieving remission is increasingly possible. In patients with well-controlled PsA, there is little consensus on whether bDMARDs should be continued, tapered or discontinued altogether. Tapering or discontinuation of bDMARDs could offer significant financial savings and minimise patient burden...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1007/s40265-018-0994-3

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Divisional Administration
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Oxford college:
St Edmund Hall
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Sub department:
Botnar Research Centre
Role:
Author
ORCID:
0000-0002-4756-663X
More from this funder
Funding agency for:
Tucker, L
Grant:
Clinical Research Fellow
More from this funder
Funding agency for:
Coates, L
Grant:
Clinician Scientist award
More from this funder
Grant:
Oxford Biomedical Research Centre
Publisher:
Springer Verlag Publisher's website
Journal:
Drugs Journal website
Volume:
78
Issue:
16
Pages:
1705–1715
Publication date:
2018-10-20
Acceptance date:
2018-10-03
DOI:
EISSN:
1179-1950
ISSN:
0012-6667
Source identifiers:
923506
Pubs id:
pubs:923506
UUID:
uuid:e3b35430-aa25-4c28-a00a-2eb39b854599
Local pid:
pubs:923506
Deposit date:
2018-10-04

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP